ArticleThe Journal of biological chemistry2010
HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.
Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 81 citations in OpenAlex.
- Role of the Proteasome System in Shaping Cellular Immunological Characteristics and Its Impact in Modulating the Pathogenesis of Immune-Related Diseases.Cells, tissues, organs · 2026Review
- Characterization of GH18 chitinase in Leishmania braziliensis: expression, structural insights, and implications for vaccine and therapeutic development.Biological research · 2026Article
- Detection of RBC-bound antibodies using flow cytometry and their correlation with HLA polymorphism.Frontiers in immunology · 2026Article
- Article
- The Primate Major Histocompatibility Complex: A Case Study of Gene Family Evolution.bioRxiv : the preprint server for biology · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Framework for analyzing MAE-derived immunopeptidomes from cell lines with shared HLA haplotypes.PloS one · 2025Article
- HBI: a hierarchical Bayesian interaction model to estimate cell-type-specific methylation quantitative trait loci incorporating priors from cell-sorted bisulfite sequencing data.Genome biology · 2024Article
- Upregulation of HLA-II related to LAG-3Cancer science · 2024Article
- In Silico Tools for Predicting Novel Epitopes.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Myeloid antigen-presenting cells in neurodegenerative diseases: a focus on classical and non-classical MHC molecules.Frontiers in neuroscience · 2024Review
- Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning.Science advances · 2023Article
- Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes.Biology · 2023Article
- New Insights on DR and DQ Human Leukocyte Antigens in Anti-LGI1 Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Review
- HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.Frontiers in immunology · 2023Review
- Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.Frontiers in immunology · 2023Review
- A combination of HLA-DP α and β chain polymorphisms paired with a SNP in the DPB1 3' UTR region, denoting expression levels, are associated with atopic dermatitis.Frontiers in genetics · 2023Article
- Article
- Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The MHC is central to the adaptive immune response. The human MHC class II is encoded by three different isotypes, HLA-DR, -DQ, and -DP, each being highly polymorphic. In contrast to HLA-DR, the intracellular assembly and trafficking of HLA-DP molecules have not been studied extensively. However, different HLA-DP variants can be either protective or risk factors for infectious diseases (e.g. hepatitis B), immune dysfunction (e.g. berylliosis), and autoimmunity (e.g. myasthenia gravis). Here, we establish a system to analyze the chaperone requirements for HLA-DP and to compare the assembly and trafficking of HLA-DP, -DQ, and -DR directly. Unlike HLA-DR1, HLA-DQ5 and HLA-DP4 can form SDS-stable dimers supported by invariant chain (Ii) in the absence of HLA-DM. Uniquely, HLA-DP also forms dimers in the presence of HLA-DM alone. In model antigen-presenting cells, SDS-stable HLA-DP complexes are resistant to treatments that prevent formation of SDS-stable HLA-DR complexes. The unexpected properties of HLA-DP molecules may help explain why they bind to a more restricted range of peptides than other human MHC class II proteins and frequently present viral peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.